Short Interest in Haleon plc (NYSE:HLN) Expands By 5.8%

Haleon plc (NYSE:HLN) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 12,420,000 shares, a growth of 5.8% from the November 15th total of 11,740,000 shares. Based on an average daily trading volume, of 6,260,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 0.3% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HLN. FMR LLC increased its holdings in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock valued at $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Clearbridge Investments LLC boosted its position in shares of Haleon by 8.6% in the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares during the period. Wellington Management Group LLP increased its stake in Haleon by 49.9% in the 3rd quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares in the last quarter. Sculptor Capital LP increased its position in shares of Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock worth $73,407,000 after acquiring an additional 3,592,000 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Haleon by 2.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company’s stock valued at $62,549,000 after purchasing an additional 196,843 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HLN. Morgan Stanley lifted their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $10.95.

Haleon Stock Performance

Shares of HLN stock opened at $9.76 on Monday. The company has a market cap of $44.18 billion, a P/E ratio of 28.71, a PEG ratio of 2.95 and a beta of 0.28. The business has a 50 day moving average of $9.75 and a two-hundred day moving average of $9.53. Haleon has a 52 week low of $7.89 and a 52 week high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.